New preclinical data on MIV-818 will be presented at the AACR Annual Meeting in April
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new preclinical data for MIV-818 will be presented during the annual meeting of the American Association for Cancer Research (AACR), which will take place 14-18 April 2018 in Chicago. MIV-818 is Medivir’s proprietary nucleotide prodrug that is being developed for the treatment of hepatocellular carcinoma and other liver cancers. The presentation will describe preclinical efficacy data on the combination of MIV-818 and sorafenib, the only agent approved in the USA as first-line treatment for advanced hepatocellular